Core Viewpoint - Tibet Pharmaceutical plans to invest $60 million in Accuredit Therapeutics Limited to acquire a 40.82% stake, aiming to enhance sustainable development and overcome R&D bottlenecks [1] Group 1: Investment Details - The investment will be made through a wholly-owned subsidiary, with the major shareholder's affiliate also investing $15 million for a 10.20% stake, resulting in a combined holding of over 51% [1] - The investment aligns with the company's strategy to focus on core business while expanding its product pipeline through both in-house and collaborative R&D efforts [1] Group 2: Target Company Overview - Accuredit Therapeutics specializes in developing in vivo gene editing technologies and products based on LNP and other non-viral vectors, aiming to provide innovative treatment solutions with cost advantages [1] - The core asset of Accuredit is its domestic holding company, Ruizheng Gene (Suzhou) Co., Ltd., which has established an end-to-end gene editing technology platform [2] Group 3: Product Pipeline - Key products in development include ART001, which targets transthyretin amyloidosis (ATTR) and has received orphan drug designation from the FDA, currently undergoing I/IIa clinical trials in China [2][3] - Another promising product, ART002, focuses on PCSK9 and shows potential to significantly reduce LDL-C levels in patients with familial hypercholesterolemia, addressing limitations of existing PCSK9 inhibitors [3] Group 4: Market Potential - The PCSK9 inhibitors market is projected to reach $4.2 billion in global sales by 2024, indicating a strong commercial outlook for ART002 [3] - Besides ART001 and ART002, Ruizheng Gene's pipeline also targets metabolic diseases, particularly in the liver, suggesting a broad potential market [4] Group 5: Company Performance - Tibet Pharmaceutical reported revenue and profit growth in the first half of 2025, driven by stable contributions from its existing products and an 18.83% increase in other product revenues [4] - The company has previously engaged in acquisitions and collaborations to expand its product line, including a $30 million investment in Chentai Pharmaceutical for a 13.04% stake [4]

Core Viewpoint - The report highlights the stable performance of Tibet Pharmaceutical (西藏药业) and its strategic investment in innovative drugs to create new growth opportunities, maintaining a "buy" rating for the stock [1]. Financial Performance - In the first half of 2025, the company achieved revenue of 1.651 billion yuan, a year-on-year increase of 2.23%. However, the net profit attributable to shareholders decreased by 8.96% to 567 million yuan. The net profit after deducting non-recurring items was 543 million yuan, up 3.69% year-on-year. The net cash flow from operating activities was 600 million yuan, an increase of 0.93% [2]. Business Operations - The main business remains robust, with the sales of the primary product, New Active Substance, reaching 4.17 million units and generating revenue of 1.456 billion yuan, accounting for 88.36% of total sales, which is a 0.41% increase year-on-year. The company is expanding its production capacity for New Active Substance, with a new production line approved and expected to reach an annual capacity of 15 million units [3]. Investor Returns - The company emphasizes investor returns through high cash dividends, distributing approximately 631 million yuan in total dividends for 2024, which is 60% of the net profit attributable to shareholders. For the first half of 2025, the company plans to distribute a cash dividend of 8.81 yuan per 10 shares, accounting for 50.05% of the net profit attributable to shareholders [4]. Strategic Investments - The company announced a plan to invest 60 million USD in Accuredit Therapeutics Limited through its wholly-owned subsidiary, acquiring a 40.82% stake. This investment is part of a broader strategy to enter the innovative drug market, with Accuredit's core asset being Suzhou Rui Zheng Gene, which has received FDA clinical approval for its gene editing products [5]. Earnings Forecast - The company forecasts revenues of 2.923 billion yuan, 3.157 billion yuan, and 3.463 billion yuan for 2025, 2026, and 2027, respectively. The net profits are projected to be 893 million yuan, 967 million yuan, and 1.066 billion yuan for the same years, with corresponding EPS of 2.77 yuan, 3.00 yuan, and 3.31 yuan. The current stock price corresponds to PE ratios of 17.6, 16.3, and 14.8 times for the respective years [6].

Investment Rating - The report maintains a "Buy" investment rating for the company [9] Core Views - The company's main business remains stable, with a slight revenue increase of 2.23% year-on-year, achieving revenue of 1.651 billion yuan in the first half of 2025. However, the net profit attributable to shareholders decreased by 8.96% to 567 million yuan [1][2] - The company is focusing on investor returns by implementing a high cash dividend policy, distributing a total of approximately 631 million yuan in dividends in 2024, which accounts for 60% of the net profit attributable to shareholders [3] - The company is investing in innovative drug companies to create new growth curves, with a planned investment of 60 million USD in Accuredit Therapeutics Limited, acquiring a 40.82% stake [4] Summary by Sections Main Business Performance - In the first half of 2025, the company achieved revenue of 1.651 billion yuan, with the main product, New Active Substance, selling 4.17 million units and generating revenue of 1.456 billion yuan, accounting for 88.36% of total revenue, a year-on-year increase of 0.41%. Other products generated revenue of 192 million yuan, a year-on-year increase of 18.83% [2] Cash Dividend Policy - The company has actively implemented stable cash dividend measures, with a proposed cash dividend of 8.81 yuan per 10 shares for the first half of 2025, which represents 50.05% of the net profit attributable to shareholders for that period [3] Investment in Innovative Drugs - The company announced an investment of 60 million USD in Accuredit Therapeutics Limited, acquiring a 40.82% stake. The core asset of Accuredit is Suzhou Rui Zheng Gene, which is the first company in China to enter clinical research for in vivo gene editing products based on LNP [4][8] Financial Forecast - The company is projected to achieve revenues of 2.923 billion yuan, 3.157 billion yuan, and 3.463 billion yuan for 2025, 2026, and 2027 respectively, with net profits of 893 million yuan, 967 million yuan, and 1.066 billion yuan for the same years [9][11]

Market Overview - The Shanghai Composite Index rose by 1.14% on August 28, with 22 out of 28 sectors experiencing gains, led by the communication and electronics sectors, which increased by 7.14% and 5.53% respectively [1] - Conversely, the coal and agriculture sectors saw declines of 0.81% and 0.73% respectively, while the pharmaceutical and biotechnology sector fell by 0.20% [1] Capital Flow Analysis - The main capital outflow from the two markets totaled 44.343 billion yuan, with five sectors experiencing net inflows. The electronics sector led with a net inflow of 10.553 billion yuan, followed by the communication sector with 4.998 billion yuan [1] - In contrast, 26 sectors faced net capital outflows, with the computer sector experiencing the largest outflow of 11.007 billion yuan, followed by the pharmaceutical and biotechnology sector with an outflow of 7.892 billion yuan [1] Pharmaceutical and Biotechnology Sector Performance - The pharmaceutical and biotechnology sector had a net outflow of 7.892 billion yuan, with 474 stocks in the sector. Out of these, 121 stocks rose, including 2 that hit the daily limit, while 346 stocks declined [2] - Notably, the top three stocks with the highest net inflow were Tibet Pharmaceutical with 320 million yuan, followed by Furuide with 293 million yuan, and Jimin Health with 126 million yuan [2] - The sector's outflow was dominated by WuXi AppTec, which saw a net outflow of 596 million yuan, followed by Borui Pharmaceutical and Hanyu Pharmaceutical with outflows of 548 million yuan and 339 million yuan respectively [3]

Market Overview - The biopharmaceutical sector experienced a slight decline of 0.14% on August 28, with Kanghong Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3843.6, up 1.14%, while the Shenzhen Component Index closed at 12571.37, up 2.25% [1] Stock Performance - Notable gainers in the biopharmaceutical sector included: - Xizang Pharmaceutical (600211) with a closing price of 48.83, up 9.00% and a trading volume of 375,100 shares, totaling 1.83 billion yuan [1] - Wendi Pharmaceutical (688488) closed at 17.78, up 5.39% with a trading volume of 137,700 shares, totaling 235 million yuan [1] - Rili Pharmaceutical (603087) closed at 71.48, up 4.40% with a trading volume of 221,400 shares, totaling 1.54 billion yuan [1] - Conversely, Kanghong Pharmaceutical (002773) saw a decline of 3.36%, closing at 39.36 with a trading volume of 173,800 shares, totaling 676 million yuan [2] - Other notable decliners included: - Bohui Innovation (300318) down 3.23% to 5.99 [2] - Jinzhenke (688670) down 3.14% to 15.40 [2] Capital Flow - The biopharmaceutical sector experienced a net outflow of 888 million yuan from institutional investors, while retail investors saw a net inflow of 941 million yuan [2] - The capital flow for specific stocks showed: - Xizang Pharmaceutical had a net inflow of 2.26 billion yuan from institutional investors, while retail investors had a net outflow of 547.24 million yuan [3] - Ganli Pharmaceutical saw a net inflow of 79.74 million yuan from institutional investors, with retail investors experiencing a net outflow of 21.51 million yuan [3]

Group 1 - The biopharmaceutical sector is experiencing active bidding, with notable stock performance including Tibet Pharmaceutical hitting the daily limit up, and Kangchen Pharmaceutical, Maiwei Biotech, and others opening higher [1] - Specific stock movements include Kangchen Pharmaceutical opening up by 5% and Maiwei Biotech also opening up by 4%, indicating positive market sentiment [1] - Other companies in the sector such as Rongchang Biotech, Hualan Vaccine, and Hualan Biotech also opened higher, reflecting a broader trend of optimism in the biopharmaceutical industry [1]

Policy Developments - The State Council aims to develop the China (Jiangsu) Pilot Free Trade Zone into a globally influential biopharmaceutical industry hub, with a plan that includes 18 key tasks for integrated innovation across the entire industry chain by 2030 [1] Drug Approvals - China Resources Double Crane announced that its subsidiaries received drug registration certificates for three products, which will enhance the company's product line and market competitiveness [2] - Tianyao Pharmaceutical's subsidiary received a drug registration certificate for a new eye drop product, which is expected to positively impact the company's domestic market expansion and performance [3] Financial Reports - China National Pharmaceutical Group reported a revenue of 17.076 billion yuan for the first half of 2025, a decrease of 6.71% year-on-year, with a net profit of 294 million yuan, down 16.19% [4] - Jiahe Meikang reported a revenue of 219 million yuan for the first half of 2025, a decline of 27.22%, resulting in a net loss of 116 million yuan [5] - Renfu Pharmaceutical reported a revenue of 12.064 billion yuan, a decrease of 6.20%, but a net profit increase of 3.92% to 1.155 billion yuan [6] Investment Activities - Tibet Pharmaceutical plans to invest 60 million USD in Accuredit Therapeutics Limited, acquiring a 40.82% stake, focusing on gene editing technologies [7] Industry Developments - The first long-acting injection for infertility treatment has been approved, providing a more efficient and convenient option for patients compared to traditional daily injections [8] - A study revealed a protein linked to infertility and cancer, suggesting potential new treatment avenues for both conditions [9] Shareholder Actions - Dabo Medical announced a plan for a shareholder to reduce their stake by up to 2% of the company's shares [10] - Kangchen Pharmaceutical's executive plans to sell up to 87,500 shares due to personal financial needs [11]

Core Viewpoint - Tibet Pharmaceutical plans to establish a wholly-owned subsidiary, TopRidge Pharma Limited, in Hong Kong to enhance sustainable development and overcome research and development bottlenecks [1] Group 1: Company Overview - Accuredit Therapeutics Limited focuses on developing in vivo gene editing technologies and products based on LNP and other non-viral vectors, aiming to provide innovative treatment solutions that require only a single administration for patients globally, with cost advantages [1] - Ruizheng Gene (Suzhou), established in 2021, specializes in the development, industrialization, and commercialization of in vivo gene editing drugs based on non-viral vectors, supported by a core team with successful experience across the entire biopharmaceutical cycle [1] Group 2: Product Pipeline - Key products under development by Ruizheng Gene include ART001, targeting transthyretin amyloidosis (ATTR), and ART002, aimed at familial hypercholesterolemia, with additional products focusing on metabolic diseases, particularly in the liver disease sector [1]

证券代码：600211 证券简称：西藏药业 公告编号：2025-031 西藏诺迪康药业股份有限公司 关于召开2025年第二次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一)股东大会类型和届次 2025年第二次临时股东大会 (二)股东大会召集人：董事会 (三)投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的方式 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025 年 9 月 15 日 14 点 30 分 召开地点：四川省成都市锦江区三色路 427 号公司办公楼会议室 (五)网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 9 月 15 日 至2025 年 9 月 15 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股东大会召 股东大会召开日期：2025年9月15日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票系统 开当日的 ...

| 四川华信(集团)会计师事务所 | 地址:成都市洗面桥街 18 号金茂礼都南 28 楼 | | --- | --- | | (特殊普通合伙) | 电话:(028) 85560449 传真:(028) 85560449 | | | 邮编:610041 | | SI CHUAN HUA XIN (GROUP) CPA (LLP) | 电邮:schxzhb@hxcpa.com.cn | Accuredit Therapeutics Limited 2024 年度及 2025年 1-6 月财务报表审计报告 川华信审(2025) 第 0675 号 目录: 您可使用手机"扫一扫"或进入"注册会计师行业统一些管理台（bms//son 1、审计报告正文 2、合并资产负债表 3、合并利润表 4、合并现金流量表 5、合并股东权益变动表 6、母公司资产负债表 7、母公司利润表 8、母公司现金流量表 9、母公司股东权益变动表 10、财务报表附注 Accuredit Therapeutics Limited 审计报告 审计报告 川华信审(2025)第 0675号 两藏诺迪康药业股份有限公司董事会: 一、审计意见 我们审计了 Accu ...